Thomas Russo

Thomas Russo is the Chief Financial Officer (CFO) of Icosavax. He has more than 25 years of diverse industry experience, including in finance and operations for public biopharma companies, as well as in the investment community. Prior to Icosavax, Tom was CFO of Assembly Biosciences, where he contributed to more than $220 million of gross proceeds raised through the capital markets and non-dilutive sources of financing. Previously, he held roles across finance and commercial operations Gilead Sciences, Inc., including serving as Vice President, Head of Commercial Finance. In that role, he supported a $20-30 billion revenue business across North America, Europe, Asia, and emerging markets. Prior to Gilead, Mr. Russo was Equity Research Senior Analyst covering biotechnology for Robert W. Baird & Co, where he earned WSJ Best on the Street recognition. Earlier in his career, he was at Merck & Co., in roles of increasing responsibility within the manufacturing division with a particular focus on vaccines. Mr. Russo received a B.S. in biological sciences from the University of Notre Dame and an MBA from the University of Chicago Booth School of Business. He is also a CFA charterholder.